Correction
In the course of type-setting this article [1] for final publication the presentation of the data in Tables 1 and 2 was altered. To avoid any confusion and to improve the clarity of our results the corrected Tables are included here.
Table 1.
Demographic and disease characteristics of patients who underwent full baseline assessment
| |
|
|
All subjects |
|||
|---|---|---|---|---|---|---|
| |
|
|
(N = 15) |
|||
| |
|
|
|
Completed |
Withdrawn |
|
| (N = 10) | (N = 5) | P | ||||
| |
|
Mean (SD) |
||||
|
Age |
(yrs) |
|
67.9 (9.4) |
67.6 (10.9) |
68.4 (6.3) |
0.88 |
|
Body mass index |
(kg/m2) |
|
23.1 (4.6) |
23.7(4.9) |
22.1(4.2) |
0.52 |
| |
|
N (%) |
||||
|
Sex | ||||||
| |
M |
|
9 (60) |
4 (40) |
5 (100) |
|
| |
F |
|
6 (40) |
6 (60) |
0 (0) |
0.04 |
|
PS | ||||||
| |
1 |
|
2 (13) |
2 (20) |
0 (0) |
|
| |
2 |
|
6 (40) |
4 (40) |
2 (40) |
|
| |
3 |
|
7 (47) |
4 (40) |
3 (60) |
0.79 |
|
Diagnosis | ||||||
| |
Lung Cancer |
|
4 (27) |
3 (30) |
1 (20) |
|
| |
GI cancer |
|
6 (40) |
2 (20) |
4 (80) |
|
| |
Other |
|
5 (33) |
5 (50) |
0 (0) |
NA |
|
Cancer stage | ||||||
| |
III |
|
1 (7) |
1 (10) |
0 (0) |
|
| |
IV |
|
11 (73) |
6 (60) |
5 (100) |
|
| |
NA |
|
3 (20) |
3 (30) |
0 (0) |
NA |
|
Chemotherapy | ||||||
| |
Y |
|
10 (67) |
6 (60) |
4 (80) |
|
| |
N |
|
5 (33) |
4 (40) |
1 (20) |
0.60 |
|
Recent steroid use | ||||||
| |
Y |
|
6 (40) |
4 (40) |
2 (40) |
|
| N | 9 (60) | 6 (60) | 3 (60) | 1.00 | ||
Notes: P indicates result of significance testing (unpaired t-test for means or Fisher’s exact test for count data) comparing patients who did, or did not complete the study.
Table 2.
Physical performance evaluation results at baseline and after 6 weeks of NMES intervention
|
Baseline |
End of study |
||||||||
|---|---|---|---|---|---|---|---|---|---|
|
All subjects |
|
||||||||
|
(N = 15) |
|
||||||||
| |
Withdrawn |
Completed |
|
Completed |
|
|
|||
| (N = 5) | (N = 10) | P a | (N = 10) | Difference | P b | ||||
| |
Number |
|
|
||||||
|
PS |
1 |
|
|
0 |
2 |
0.79# |
4 |
|
0.15# |
| |
2 |
|
|
2 |
4 |
|
4 |
|
|
| |
3 |
|
|
3 |
4 |
|
2 |
|
|
| |
Mean (SD) |
|
|
||||||
|
6MWT |
m |
|
257(160) |
166 (138) |
303 (157) |
0.11 |
282 (171) |
−21.1 (167.7) |
0.70 |
| |
% |
|
50.2 (32.2) |
31.0(24.6) |
59.8(32.2) |
0.08 |
56.0(34.5) |
−3.8 (33.3) |
0.73 |
|
STS |
s |
|
8.0(4.3) |
7.6 (3.4) |
8.2 (4.8) |
0.80 |
7.0(3.3) |
−1.2 (3.4) |
0.30 |
| S-score | 2.6(2.4) | 2.2 (2.0) | 2.7 (2.2) | 0.69 | 2.0(1.8) | −0.7 (2.0) | 0.30 | ||
Notes: Performance status (PS), six-minute walk distance (6MWT) in metres (m) and expressed as % predicted (from [21]), Sit-to-stand (STS) test expressed as seconds (s) and as a standard score (S-score) value calculated using age range-specific mean and standard deviations for healthy controls (from [22]): positive scores indicates STS S-scores above the mean. Pa: #Fisher’s exact (for counts) or unpaired t-test (for means) comparing baseline results for patients withdrawn and patients who completed study. Pb: #Fisher’s exact (for counts) or paired t-test (for means) comparing baseline and final test results for patients who completed the study.
Pre-publication history
The pre-publication history for this paper can be accessed here:
Contributor Information
Tamara Windholz, Email: twindholz@jgh.mcgill.ca.
Tara Swanson, Email: tara.swanson@mail.mcgill.ca.
Brandy L Vanderbyl, Email: brandy.vanderbyl@mail.mcgill.ca.
R Thomas Jagoe, Email: thomas.jagoe@mcgill.ca.
References
- Windholz T, Swanson T, Vanderbyl BL, Jagoe RT. The feasibility and acceptability of neuromuscular electrical stimulation to improve exercise performance in patients with advanced cancer: a pilot study. BMC Palliat Care. 2014;13:23. doi: 10.1186/1472-684X-13-23. [DOI] [PMC free article] [PubMed] [Google Scholar]